Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986527 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1: BMS-986527 monotherapy | EXPERIMENTAL | - |
| Cohort 2: BMS-986527 with Nivolumab | EXPERIMENTAL | - |
| Cohort 3: BMS-986527 with Cabozantinib | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986527 | DRUG | Specified dose on specified days |
| Nivolumab | DRUG | Specified dose on specified days |
| Cabozantinib | DRUG | Specified dose on specified days |
Inclusion Criteria * Participants must have a histologically confirmed diagnosis of a locally advanced and unresectable or metastatic renal cell carcinoma (RCC) with clear cell component. * Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Participa...
BMS-986527 is an investigational small molecule being developed by Bristol-Myers Squibb for the treatment of clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer. It is currently in Phase 1 clinical development and has not been approved by the FDA.
BMS-986527 is being studied for use in clear cell renal cell carcinoma (ccRCC), a type of kidney cancer. It is an investigational therapy in Phase 1 testing, so its use is currently limited to clinical trial participants rather than routine clinical practice.
Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY, is the developer of BMS-986527. The company is sponsoring the clinical program evaluating the small molecule in clear cell renal cell carcinoma.
BMS-986527 is in Phase 1 clinical development. It is an investigational small molecule and has not received FDA approval. The Phase 1 program is designed to assess safety and tolerability in participants with clear cell renal cell carcinoma.
BMS-986527 is being evaluated in one clinical trial, NCT07848295, titled A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC). The Phase 1 study is not yet recruiting and plans to enroll 112 participants across the United States, Belgium, France, Germany, Italy, Netherlands, and Spain.
The Phase 1 trial NCT07848295 enrolls adults 18 years and older of any sex who have clear cell renal cell carcinoma. It does not enroll healthy volunteers. The study is controlled, is not randomized, and is not double blinded, and it plans to enroll 112 participants across seven countries.